Bone Infarct-Associated Osteosarcoma: Epidemiologic and Survival Trends

Area of Science:

• Orthopedic Oncology
• Bone Tumors
• Sarcoma Research

Background:

• Secondary osteosarcoma (SO) arising from bone infarcts is a rare condition with a poor prognosis.
• Limited literature exists on the specific characteristics and treatment outcomes for SO on bone infarct.
• This study aimed to further define this rare disease and assess the impact of chemotherapy (ChT) on patient survival.

Purpose of the Study:

• To characterize the main features of secondary osteosarcoma on bone infarct.
• To determine the overall survival (OS) rates for patients with this condition.
• To evaluate the influence of chemotherapy (ChT) treatment on OS and compare findings with existing literature.

Main Methods:

• Retrospective review of 11 cases of SO on bone infarct (cohort 1) at Rizzoli Orthopedic Institute (1992-2018).
• Epidemiological, surgical, and ChT treatment data were analyzed.
• Comparison with 14 case reports from literature (cohort 2) published between 1962-2018.

Main Results:

• The study cohort comprised 11 patients (median age 55), with tumors predominantly on the distal femur (64%).
• Five-year OS was 62% for cohort 1. Patients receiving ChT showed a 71% 5-year OS compared to 50% for surgery alone (p=0.4773).
• Median survival was significantly longer for cohort 1 (74 months) compared to cohort 2 (12 months) (p=0.0247), indicating improved outcomes.

Conclusions:

• Chemotherapy (ChT) in combination with surgery appears to improve survival rates for patients with secondary osteosarcoma on bone infarct.
• The findings suggest that a multimodal treatment approach is beneficial for this rare bone tumor.
• Further research into optimizing treatment strategies for SO on bone infarct is warranted.